NCT05823480 2024-09-19Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSCity of Hope Medical CenterPhase 1 Withdrawn
NCT05367401 2024-04-11A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsNovartisPhase 1/2 Withdrawn
NCT02678338 2019-02-21CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesGilead SciencesPhase 1 Completed20 enrolled